Robert Hammer, Ph.D.

• Genome editing and transgenesis
• Oncogene and nutrient collaboration in cancer
• Ribosomopathies
• Rodent models of cancer

 Featured Publications

Dual genetic pathways of endothelin-mediated intercellular signaling revealed by targeted disruption of endothelin converting enzyme-1 gene.

Yanagisawa, H., Yanagisawa, M., Kapur, R.P., Richardson, J.A., Williams, S.C., Clouthier, D.E., de Wit, D., Emoto, N., and Hammer, R.E. Development. 1998 125 825-836

Hepatic fibrosis, glomerulosclerosis, and a lipodystrophy-like syndrome in PEPCK-TGF-beta1 transgenic mice.

Clouthier, D.E., Comerford, S.A., and Hammer, R.E. J. Clin. Invest. 1997 100 2697-2713

E6 and E7 expression from the HPV 18 LCR: development of genital hyperplasia and neoplasia in transgenic mice.

Comerford, S. A., Maika, S.D., Laimins, L.A., Messing, A., Elsasser, H.P., and Hammer, R.E. Oncogene 1995 10 587-597

• State Capital of Wiesbaden, Germany
  Carol-Nachman Prize in Rheumatology (1992)
• USDA Unit Award for Distinguished Service
  Application of Gene Transfer to Farm Animals (1989)
• University of Pennsylvania School of Veterinary Medicine
  NIH Postdoctoral Fellowship (1983)

• International Society for Stem Cell Research (ISSCR) (2018)
• International Society of Transgenic Technology (ISTT) (2010)
• Public Responsibility in Medicine and Research (PRIMR) (2016)
• Society for Developmental Biology (2020)